Risankizumab Is Effective for The Management of Crohn's Disease of the Pouch

In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammatory bowel diseases 2024-07
Hauptverfasser:	Kayal, Maia, Spencer, Elizabeth A, Smyth, Matthew, Raffals, Laura, Qazi, Taha, Deepak, Parakkal, Beniwal-Patel, Poonam, Chang, Shannon, Higgins, Peter, Cross, Raymond K, Anderson, Chelsea, Long, Millie, Herfarth, Hans H, Dubinsky, Marla C, Barnes, Edward L
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.
ISSN:	1078-0998 1536-4844 1536-4844
DOI:	10.1093/ibd/izae164